Company: DMAAR
Filing Date: 2025-11-18
Form Type: 10-Q
Source: 0001213900-25-112096
Chunk: 29

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-11-18
Form: 10-Q
Item: Part I, Item 1
Chunk 29
---
 — The Company is authorized to issue 220,000,000 ordinary shares with a par value of $0.0001 per share.
Holders of ordinary shares are entitled to one vote for each share. As of September 30, 2025 and December 31, 2024, there are 10,517,143
and 9,857,143 ordinary shares issued and outstanding, excluding 23,000,000 and 0 share subject to redemption, respectively. Of the ordinary
shares outstanding at December 31, 2024, an aggregate of up to 1,285,714 ordinary shares were subject to surrender and forfeiture to
the extent that the underwriters’ over-allotment option was not exercised in full or in part so that the number of Founder Shares
would equal 30% of the Company’s issued and outstanding ordinary shares after the Initial Public Offering (not including the Private
Placement Units and the representative shares and assuming Sponsor does not purchase any Public Shares in the Initial Public Offering).
In February 2025 the over-allotment option was exercised in full by the underwriters and these shares are no longer subject to forfeiture.

Rights — Except
in cases where the Company is not the surviving company in a Business Combination, each holder of a right will automatically receive
one-eighth (1/8) of one ordinary share upon consummation of the initial Business Combination. The Company will not issue fractional shares
in connection with an exchange of rights. Fractional shares will either be rounded down to the nearest whole share or otherwise addressed
in accordance with the applicable provisions of Cayman law. In the event the Company is not the surviving company upon completion of
the initial Business Combination, each holder of a right will be required to affirmatively convert his, her or its rights in order to
receive the one-eighth (1/8) of one ordinary share underlying each right upon consummation of the Business Combination. If the Company
is unable to complete the initial Business Combination within the required time period and the Company will redeem the public shares
for the funds held in the Trust Account, holders of rights will not receive any of such funds for their rights and the rights will expire
worthless.

15

DRUGS
MADE IN AMERICA ACQUISITION CORP.

NOTES
TO FINANCIAL STATEMENTS

SEPTEMBER
30, 2025

(Unaudited)

Representative
Shares — The Company issued to Clear